MH

Martin Heidecker

Chief Investment Officer AMR Action Fund

Cambridge, Massachusetts

Investor
VC

Invests in

Stages:

Series A
Seed

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Skills

Pharmaceutical Industry
Oncology
Biotechnology
Market Research
Lifesciences
Clinical Development
Market Access
Biopharmaceuticals
Business Analysis
Drug Discovery
Neurology
Market Analysis
Pharmaceutical Sales
Drug Development
Technology Transfer
Global Marketing
Sales Effectiveness
Competitive Intelligence
Cardiology
Clinical Trials

Education

Investments

Vedanta Biosciences

Series E

Total Funding: $110M

BioVersys

Series C

Total Funding: $9M

Venatorx Pharmaceuticals

Series C

Total Funding: $76M

Adaptive Phage Therapeutics

Series B

Total Funding: $61M

Libra Therapeutics

Series A

Total Funding: $29M

Rgenta Therapeutics

Seed

Total Funding: $90M

Sentien Biotechnologies

Series A

Total Funding: $12M

Sentieon

Series A

Total Funding: $4M

ArmaGen Technologies

Series A

Total Funding: $17M

Work Experience

AMR Action Fund

2020

  • Chief Investment Officer

    2021

  • Member Board of Directors AMR action

    2020 - 2021

MassBio

2020

  • Board Member MassBio Biotechnology

    2020

Libra Therapeutics

2020 - 2021

  • Member Board of Directors Libra Therapeutics Inc.

    2020 - 2021

Tiga Therapeutics Inc.

2020 - 2021

  • Member Board of Directors Tiga Tx Inc.

    2020 - 2021

Rgenta Therapeutics Inc.

2020 - 2021

  • Member Board of Directors Rgenta Therapeutics Inc.

    2020 - 2021

Abexxa Biologics, Inc.

2016 - 2021

  • Member Board of Directors Abexxa Biologics Inc.

    2016 - 2021

Sentien Biotechnologies, Inc.

2015 - 2021

  • Member Board of Directors

    2015 - 2021

Boehringer Ingelheim Venture Fund USA Inc.

2013 - 2021

  • Managing Director BIVF USA Inc.

    2013 - 2021

    Run Boehringer Ingelheim Venture Fund offices in the United States, scout for early investment opportunities in Cambridge and other sites of innovation and lead respective Due Diligence, invest in start-up biotech companies and represent BIVF US as a Board Director.

ArmaGen Technologies

2012 - 2020

  • Member Board of Directors

    2012 - 2020

121 Bio LLC

2014 - 2016

  • Member Board of Directors

    2014 - 2016